Dr. Dennis L. Carter, MD

Dr. Carter practices at Rocky Mountain Cancer Centers in Aurora, Colorado.

Dr. Carter's NPI, 1740264480, was assigned on December 6, 2005. Dr. Carter graduated from University Of Washington School Of Medicine in 1993. Dr. Carter holds Colorado license DR.0039243.

Dr. Carter's primary practice is Rocky Mountain Cancer Centers, at 1700 S Potomac St, Aurora, CO 80012 in Arapahoe County. The practice phone is (303) 930-7800.

Dr. Carter's primary practice is Rocky Mountain Cancer Centers in Aurora, Colorado. The medical group on file is Rocky Mountain Cancer Centers.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Carter practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Carter's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Carter is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Carter's licenses on file in 2 states: Colorado and North Carolina.

Dmand AI lists bladder cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation and head & neck cancer radiation among the conditions Dr. Carter treats.

CMS data shows 13,989 Medicare services from Dr. Carter across 27 procedure codes in 2024, for 288 Medicare patients. Medicare paid $276,966 for them.

CMS counts 288 Medicare patients who saw Dr. Carter in 2024. The largest group is 65 to 74, with 144 patients. 69% of them have high blood pressure, and 67% have cancer. 9% are also on Medicaid. Their average risk score is 2.02, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Carter's median patient age at 74, with 51% women.

In 2024, Dr. Carter wrote 61 Medicare Part D claims for 32 patients. 90% of them were for generic drugs. CMS names the drug for 20 of them, across 1 drug with 11 or more claims each, at $250 in total drug cost. In 2021, CMS named 15 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 73 out of 100 for Dr. Carter for performance year 2024, reported through an alternative payment model (APM). Dr. Carter accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Carter as offering telehealth.

Dmand AI links 13 papers to Dr. Carter, published from 2008 to 2021. 2021 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Carcinoma, Squamous Cell and Dose Fractionation, Radiation. Dr. Carter's most frequent co-authors are Charles E. Leonard, MD, Andrew Scott Kennedy, MD and Steven C. Rose, MD.

Dmand AI links Dr. Carter to 4 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Carcinoma, Intraductal, Noninfiltrating, Breast Carcinoma In Situ and Colonic Neoplasms. Rocky Mountain Cancer Centers sponsors the most, 3.

CMS Open Payments shows 40 general payments to Dr. Carter from 18 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $234.

Dmand AI lists 1 award for Dr. Carter, most recently CMS Stage 1 EHR in 2014.

Dr. Carter graduated from University Of Washington School Of Medicine in 1993.

Dr. Carter is in network with 16 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.